InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Silexion Therapeutics Corp

SLXN Clue Score15
Israel Fiscal year ends December CIK 0002022416
$0.21 -8.64% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.21 −94.64% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Aug 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−4.7Net income−5.1EPS, diluted44.23Fiscal year 2024Operating income−12.6Net income−16.5EPS, diluted394.94Fiscal year 2025Operating income−11.6Net income−11.9EPS, diluted8.96
FY2023FY2024FY2025
Operating income −4.7 −12.6 −11.6
Net income −5.1 −16.5 −11.9
Growth
EPS, diluted 44.23 394.94 8.96

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−4.5Capital expenditure−0.0Free cash flow−4.5Fiscal year 2024Operating cash flow−8.4Capital expenditure−0.0Free cash flow−8.4Fiscal year 2025Operating cash flow−10.8Capital expenditure−0.0Free cash flow−10.8
FY2023FY2024FY2025
Operating cash flow −4.5 −8.4 −10.8
Capital expenditure −0.0 −0.0 −0.0
Free cash flow −4.5 −8.4 −10.8
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash4.6Shareholders’ equity−15.5Fiscal year 2024Cash1.2Shareholders’ equity−4.0Fiscal year 2025Cash6.0Shareholders’ equity2.6
FY2023FY2024FY2025
Cash 4.6 1.2 6.0
Shareholders’ equity −15.5 −4.0 2.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
3.7 5.8 7.1
1.0 6.8 4.5
−4.7 −12.6 −11.6
Growth
−5.1 −16.5 −11.9
0.0 0.0 0.0
−5.1 −16.5 −11.9
Growth
Per share
44.23 394.94 8.96
44.23 394.94 8.96
Growth +792.9% −97.7%
0.1 0.0 1.3
0.1 0.0 1.3
Growth −62.7% +3,093.3%

† The diluted share count jumps at 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 3 of 3 years on file.